NCCN antiemesis practice guidelines

ONCOLOGY

Volumn 11, Issue 11 SUPPL. 11A, 1997, Pages 57-89

  Ettinger, David S ^a   Huber, Steven ^b   Kris, Mark G ^c   Levy, Michael ^d   McNulty, Robert ^e   Noonan, Kimberly Rogers ^f   Stucky Marshall, Lisa ^g   Urba, Susan ^h   Wood, James G ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; BENZAMIDE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BUTYROPHENONE DERIVATIVE; CANNABINOID; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; DROPERIDOL; GRANISETRON; HALOPERIDOL; LORAZEPAM; METOCLOPRAMIDE; ONDANSETRON; PHENOTHIAZINE DERIVATIVE; PROCHLORPERAZINE; SEROTONIN ANTAGONIST; THIETHYLPERAZINE MALEATE;

BEHAVIOR THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMORECEPTOR; COST EFFECTIVENESS ANALYSIS; HYPNOSIS; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; REVIEW; VOMITING; WHOLE BODY RADIATION;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; DATABASES, FACTUAL; EMETICS; FLORIDA; HUMANS; NAUSEA; NEOPLASMS; PRACTICE GUIDELINES; VOMITING;

EID: 0031467942     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Ingle RJ, Burish TG, Wallston KA: Conditionability of cancer chemotherapy patients. Oncol Nurs Forum 11:97-102, 1984.
2. Laszlo J: Emesis as limiting toxicity in cancer chemotherapy, in Laszlo J (ed): Antiemetics and Cancer Chemotherapy, pp 1-5. Baltimore. Maryland, Williams & Wilkins. 1983.
3. Mitchell EP: Gastrointestinal toxicity of chemotherapeutic agents. Semin Oncol 19:566-579, 1992.
4. Richardson JL, Marks G, Levine A: The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol 5:1746-1752, 1988.
5. Jenns K: Importance of nausea. Cancer Nurs 17:488-493, 1994.
6. Morran C, Smith DC, Anderson DA, et al: Incidence of nausea and vomiting with cytotoxic chemotherapy: A prospective randomized trial of antiemetics. Br. Med J 1:1323-1324, 1979.
7. Carey MP, Burish TG: Anxiety as a predic- tor of behavioral therapy outcome for cancer chemotherapy patients. J Consult Clin Psychol 53:860-865, 1985.
8. Morrow GR, Lindke J, Black PM: Predicting development of anticipatory nausea in cancer patients: Prospective examination of eight clinical characteristics. J Pain Symptom Manag 6:215-223, 1991.
9. Nesse RM, Carli T, Curds GC, et al: Pretreatment nausea in cancer chemotherapy: A conditioned response? Psychosom Med 42:33-36, 1980.
10. Wilcox PM, Fetting JH, Nettesheim KM, et al: Anticipatory vomiting in women receiving cyclophosphamide. methotrexate. and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. Cancer Treat Rep 66:1601-1604, 1982.
11. Craig JB, Powell BL: The management of nausea and vomiting in clinical oncology. Am J Med Sci 293:34-44, 1987.
12. Borison HL, Wang S: Physiology and pharmacology of vomiting. Pharmacol Rev 5:193-230, 1953.
13. Siegel LJ, Longo DL: The control of che- motherapy-induced emesis. Ann Intern Med 95:352-359, 1981.
14. Dodds LJ: The control of cancer chemotherapy-induced nausea and vomiting. J Clin Hasp Pharm 10:143-166, 1985.
15. Kris MG, Gralla RJ, Clark RA, et al: Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 3:1379-1384, 1985.
16. Roila F, Boschetti E, Tonato M, et al: Predictive factors of delayed emesis in cisplatin patients and anti-emetic activity and tolerability of metoclopramide or dexamethasone. Am J Clin Oncol 14:238-242, 1991.
17. Jacobsen PB, Redd WH: The development and management of chemotherapy-related anticipatory nausea and vomiting. Cancer Invest 6:329-336, 1988.
18. Moher D, Arthur AZ, Peter JL: Anticipatory nausea and/or vomiting in chemotherapy patients. Cancer Treat Rev 11:257-264, 1984.
19. Morrow GR: Clinical characteristics associated with the development of anticipatory nau- sea and vomiting in cancer patients undergoing chemotherapy treatment. J Clin Oncot 2:1170-1176, 1984.
20. Harding RK, Young RW, Anno GH: Radiotherapy-induced emesis, in Andrews PLR, Sanger GJ (eds): Emesis in Ami-Cancer Therapy. pp 163-178. London. Chapman & Hall Medical, 1993.
21. Laszlo J: Treatment of nausea and vomiting caused by cancer chemotherapy. Cancer Treat Rev 9:3-9, 1982.
22. Strum SB, McDermed JE, Pileggi J, et al: Intravenous metoclopramide: Prevention of chemotherapy-induced nausea and vomiting. Cancer 53:1432-1439, 1984.
23. Lindley CM, Bernard S, Fields SM: Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol 7:1142- 1149, 1989.
24. Aapro MS: Methodological issues in antiemetic studies. Invest New Drugs 11:243-253, 1993.
25. Hesketh PH, Kris MG, Grunberg, SM et al: Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103-109, 1997.
26. Wampler G: The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapy-induced emesis. Drugs 25:31-51, 1983.
27. Gralla RJ, Braun TJ, Itri LM, et al: Antiemetic efficacy of high-dose metoclopramide. Randomized trials with placebo and prochloroperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305:905-909, 1981.
28. Gralla RJ, Tyson LB, Borden LA, et al: Antiemetic therapy: A review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannibinol. Cancer Treat Rep 68:163-172, 1984.
29. Bakowski MT: Advances in anti-emetic therapy. Cancer Treat Rev 11:237-256, 1984.
30. Grossman B, Lessen LS, Cohen P: Droperidol prevents nausea and vomiting from cisplastinum (letter). N Engl J Med 301:7, 1979.
31. Aapro MS, Alberts DS: High dose dexamethasone for prevention of cisplatinum-induced vomiting. Cancer Chemother Pharmacol 7:11-14, 1981.
32. Aapro MS, Plezia PM, Alberts DS, et al: Double-blind crossover study of the antimetic efficacy of high-dose dexamethasone vs highdose metoclopramide (abstract). Proc Am Soc Clin Oncol 2:93, 1983.
33. Cassileth PA, Lusk EJ, Torri S, et al: Antimetic efficacy of dexamethasone therapy in pa- tients receiving chemotherapy. Arch Intern Med 143:1347-1347, 1983.
34. Kris MG, Gralla RJ, Clark RA, et al: Consecutive dose finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: Improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. Cancer Treat Rep 69:1257-1262, 1984.
35. Kris MG, Gralla RJ, Clark RA, et al: Antiemetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in conjunction with metoclopramide plus dexamethasone: A double-blind, randomized trial. Cancer 69:1353-1357, 1987.
36. Herman TS, Einhorn LH, Joncs SE: Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 200:1295-1297, 1979.
37. Steele N, Gralla RJ, Braun DW, et al: Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep 64:219-224, 1980.
38. Hesketh PJ, Gandara DR: Serotonin antagonists; A new class of antiemetic agents. J Natl Cancer Inst 83:613-620, 1991.
39. Andrews PLR. Bhandari P, Davey PT et al: Are all 5-HT receptor antagonists the same? Eur J Cancer 28A:S2-6, 1992.
40. Chevallier B: Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. Eur J Cancer 26(suppl 1):S33-36, 1990.
41. Chevallier B: The control of acute cisplatin-induced emesis - A comparative study of granisetron and combination regimen of high-dose metoclopramide and dexamethasone. Br J Cancer 68:176-180, 1993.
42. Cupissol DR, Serrou B, Caubel M: The efficacy of granisetron as prophylactic antiemetic and intervention agent in high-dose cisplatin-induced emesis. Eur J Cancer 26:323-27, 1990.
43. DeMulder PHM, Seynaeve C, Vermorken JB, et al: Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 113:834-840, 1990.
44. Grunberg SM, Stevenson LL, Russell CA, et al: Dose ranging phase I study of the serotonin antagonist GR 38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 7:1137-1141, 1989.
45. Kamanabrou D: Intravenous granisetron-establishing the optimal dose. Eur J Cancer 28A(suppl 1):S6-11, 1992.
46. Marty M: A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. Eur J Cancer 26(suppl l):S28-32, 1990.
47. Navari RM, Kaplan HG, Gralla RJ, et al: Efficacy and safety of granisetron, a selective 5-HT, antagonist, in the prevention of nausea and vomiting induced by high dose cisplatin. J Clin Oncol 12:2204-2210, 1994.
48. Riviere A: Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 69:967-971, 1994.
49. Roila F, Tonato M, Cognetti F, et al: Prevention of cisplatin-induced emesis: A double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 9:675-678, 1991.
50. Sledge GW Jr, Einhorn L, Nagy C, et al: Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer 70:2524-2528, 1992.
51. Soukop M: A comparison of two dose levels of granisetron in patients receiving highdose cisplatin. Eur J Cancer 26(suppl 1):S15-19, 1990.
52. Fraschini G: Antiemetic activity of ondansetron in cancer patients receiving non-cisplatin chemotherapy. Semin Oncol 19(suppl 10):41-47, 1992.
53. Marty M, Pouillart P, School S, et al: Comparison of the 5hydroxytryptamine3 (serotonin) receptor anatagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322:816-821, 1990.
54. Bonneterre J, Hecquet B, French Northern Oncology Group: Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy: A cross over study. Bulletin du Cancer 82:1038-43, 1982.
55. Noble A, Bremer K, Goedhals L et al: A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. Eur J Cancer 30(8):1083-1088, 1994.
56. Navari R, Gandara D, Hesketh P, et al: Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 13(5): 1242-1248, 1995.
57. Ruff P, Paska W, Goedhals L, et al: Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology 51:113-118, 1994.
58. Stewart A, McQuade B, Cronje JDE et al: Ondansetron compared with granisetron I the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double dummy, randomised, parallel-group study. Oncology 52:202-210, 1995.
59. Gebbia V, Cannata G, Testa A, et al: Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer 74(7):1945-1952, 1994.
60. Martoni S, Angelelli B, Guaraldi M, et al: Granisetron (GRA) vs. ondansetron (OND) in the prevention of cisplatinum-induced emesis: An open randomized cross-over study. Am Soc Lin Oncol 13:431, 1993.
61. Leonardi V, Iannitto E.,Meli M, Palmen S, Ondansetron vs granisetron in the control of chemotherapy induced acute emesis: A multicentric randomized trial Oncology Rep 3:919-923, 1996.
62. Italian Group for Antiemetic Research. Ondansetron versus granisetron. both combined with dexamethasone. in the prevention of cisplatin-induced emesis. Ann Oncol 6:805-810, 1995.
63. Marty M, Kleisbauer J-P, Fournel P, et al: Is navoban (tropisetron) as effective as zofran (ondansetron) in cisplatin-induced emesis? Anti-Cancer Drugs 6(suppl 1):15-21, 1995.
64. Jantunen IT, Kataja VV, Johansson RT: Ondansetron and tropisetron with dexamethasone in the prophylaxis of acute nausea and vomiting induced by non-cisplatin-containing chemother- apy. Acta Oncol 31(3):573-575, 1992.
65. Campora LE, Simoni C, Rosso R: Tropisetron verso ondansetron nella prevenzione e controllo dell: emesi in pazienti sottoposte a chemioterapia con FAC/FEC per carcinoma mammario metastatico o operato. Minerva Med 85:25-31, 1994.
66. Massidda B, Laconi S, Foddi MR et al: Prevention of non-cisplatin induced emesis: Role of the antagonists of 5-HT, receptors. Ann Oncol 5(suppl 8):204, 1994.
67. Mantovani A, Maccio L, Curreli L, et al: Camparison of the effectiveness of three 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by highly emetogenic chemotherapy (high-dose cisplatin) for the treatment of primary head and neck cancer. Proc Soc Am Clin Oncol 13:428, 1994.
68. Jantunen IT, Muhonen TT, Kataja VV, et al: 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy a randomised study. Eur J Cancer 29A: 1669-1672, 1993.
69. Hesketh P, Navari R, Grote T, et al: Double-blind, randomised comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 14(8):2242-2249, 1996.
70. Audhuy B, Cappelaere P, Martin M, et al: A double-blind. randomised comparison of the antiemetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 32A(5):807-813, 1996.
71. Fauser AA, Duclos B, Chemaissani A, et al: Therapeutic equivalence of single oral doses of dolasetron mesylate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. Eur J Cancer 32A:1523-1529, 1996.
72. Lofters WS, Paler JL, Zee B, et al: Phase III double-blind comparison of dolasetron mesylate and ondansetron and and evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 15:2966-2973, 1997.
73. Kris MG, Gralla RJ, Johnson LB, et al: Controlling delayed vomiting: double-blind randomized trial comparing placebo, dexamethasone alone and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 7:108-114, 1989.
74. Shinkai T, Saijo N, Eguchi K, et al: Control of cisplatin-induced delayed emesis with metoclopramide and dexamethasone: A randomized controlled trial. Jpn J Clin Oncol 19:40-44, 1989.
75. Ossi M, Anderson E, Freeman A: 5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis. Oncology 53(suppl l):78-85, 1996.
76. Gandara DR, Harvey WH, Monaghan GG, et al: The delayed-emesis syndrome from cisplatin: Phase III evaluation of ondansetron versus placebo. Semin Oncol 19:67-71, 1992.
77. Franzen L, Nyman J, Hagberg H, et al: A randomized placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy. Ann Oncol 7:587-592, 1996.
78. Belkacemi Y, Ozsahim M, Pene F, et al: Total body irradiation prior to bone marrow transplantation: Efficacy and safety of granisetron in the prophylaxis and control of radiation-induced emesis. Im J Radiation Oncol Biol Phys 36:77-82, 1996.
79. Okamoto S, Takahashi S, Tanosaki R, et al: Granisetron in the prevention of vomiting induced conditioning for stem cell transplantation: A prospective randomized study. Bone Marrow Transplantation 17:679-683, 1996.
80. Morrow GR, Morrell C: Behavioral treatment for the anticipating nausea and vomiting induced by cancer chemotherapy. .V Engl J Med 307:1476-1480, 1982.
81. Redd WH, Andrykowski MA: Behavioral intervention in cancer treatment: Controlling aversion reactions to chemotherapy. J Consult Clin Psychol 50:1018-1029, 1982.
82. Razavi D, Delvaux N, Farvacques C, et al: Prevention of adjustment disorders and anticipation nausea secondary to adjuvant chemotherapy: A double-blind, placebo-controlled study of assessing the usefulness of alprozolam. J Clin Oncol 11:1384-1930, 1993.